Courtesy of SBHCI. Patients with severe aortic stenosis and low surgical risk showed decreased mortality, stroke, and heart failure hospitalization at one year with transcatheter aortic valve replacement compared with surgery. Improved quality of life may seem an obvious consequence, but until now that was mere speculation. This work, presented at the TCT 2019 Scientific Sessions<a href="https://solaci.org/en/2019/10/01/tct-2019-partner-3-obvious-short-term-quality-of-life-improvement-but-what-happens-afterwards/" title="Read more" >...</a>
TCT 2019 | COAPT Cost Effectiveness: Better Quality of Life and Survival Rate, but Worth It?
Courtesy of SBHCI. The COAPT showed transcatheter repair of the mitral valve using the MitraClip resulted in reduced mortality and hospitalization for cardiac failure and improved quality of life, compared against optimal medical treatment in patients with cardiac failure and moderate to severe functional mitral regurgitation. The cost-effectiveness of this procedure has not been analyzed<a href="https://solaci.org/en/2019/10/01/tct-2019-coapt-cost-effectiveness-better-quality-of-life-and-survival-rate-but-worth-it/" title="Read more" >...</a>
TCT 2019 | PARTNER 2A at 5 Years: In Intermediate-Risk Patients, TAVR Is Still Head-to-Head with Surgery
Courtesy of the SBHCI. The 2-year results of the PARTNER 2A trial showed that transcatheter aortic valve implantation has a result similar to that of surgery in patients with aortic stenosis and intermediate surgical risk. We lacked long-term data, both clinical and related to prosthesis function. Now, at TCT 2019, researchers presented the 5-year data for this<a href="https://solaci.org/en/2019/10/01/tct-2019-partner-2a-at-5-years-in-intermediate-risk-patients-tavr-is-still-head-to-head-with-surgery/" title="Read more" >...</a>
TCT 2019 | STS/ACC TVT Registry: Relationship Between MitraClip Operator Experience and Events
Courtesy of SBHCI. Mitral valve repair with a MitraClip device is a complex procedure that requires that operators develop a series of skills that may be unusual for them, such as analyzing an echocardiography. In this registry, researchers assessed the relationship between operator experience and procedural outcome. Operators were classified into 3 groups: 1 to 25 procedures<a href="https://solaci.org/en/2019/09/30/tct-2019-sts-acc-tvt-registry-relationship-between-mitraclip-operator-experience-and-events/" title="Read more" >...</a>
Very Encouraging Results for TAVR in Low-Risk Patients
Courtesy of Dr. Carlos Fava. About 12% of patients >75 years old have aortic stenosis. In 3%-4% of them, such disease is severe. Transcatheter aortic valve replacement (TAVR) has already proven to be beneficial for extreme-, high-, and intermediate-risk patients. Regarding low-risk patients, we currently have different analyses; two of them are randomized and their results are<a href="https://solaci.org/en/2019/09/30/very-encouraging-results-for-tavr-in-low-risk-patients/" title="Read more" >...</a>
TAVR and Pacemakers, New Strategies
Courtesy of Dr. Carlos Fava. TAVR has been shown beneficial and is constantly being advanced onto lower risk populations, but at present, it is limited (perhaps most importantly in aortic tricuspid valves) by the need for permanent pacemaker implantation (PPMI), especially when it comes to self-expandable valves, as the latest study on low risk populations<a href="https://solaci.org/en/2019/09/30/tavr-and-pacemakers-new-strategies/" title="Read more" >...</a>
TAVR in Bicuspid Has the Same Results in Surgery at Hospital Level
Courtesy of Dr. Carlos Fava. Bicuspid aortic stenosis patients (bicuspid AS) represent a small group and have not been included in the larger transcatheter aortic valve replacement (TAVR) studies, since they present different morphology and asymmetric calcification, which might come along with more paravalvular leak and less accurate positioning. Between 2012 and 2016, 475,315 patients<a href="https://solaci.org/en/2019/09/24/tavr-in-bicuspid-has-the-same-results-in-surgery-at-hospital-level/" title="Read more" >...</a>
The Most Read Articles of August in solaci website
1-FDA Expands TAVR Indication to Low-Risk Patients Both the self-expandable valve Evolut R and its direct competitor, balloon-expandable valve Sapien 3, received the authorization to be indicated for low-risk patients in a long-awaited announcement made on August 16th, 2019. Read also HERE 2-Mechanisms of Post PCI Persistent Angina Angina persistence or recurrence after PCI can<a href="https://solaci.org/en/2019/09/16/the-most-read-articles-of-august-in-solaci-website/" title="Read more" >...</a>
MitraClip in the Real World: Mid-Term Progress
Courtesy of Dr. Carlos Fava. The fact that the outcomes of edge-to-edge repair with MitraClip have improved, particularly in the immediate and short term, is widely known. Such improvement is basically a result of more operator experience and the arrival of 3-D echocardiography. However, there are no mid-term follow-up studies available, except for the EVEREST<a href="https://solaci.org/en/2019/09/16/mitraclip-in-the-real-world-mid-term-progress/" title="Read more" >...</a>
To the Beat of SOLACI-CACI 2020: An Interview with Dr. Aníbal Damonte
After yet another successful SOLACI Congress, we are renewing our energy by preparing for our next event, SOLACI-CACI 2020, which will take place from February 28th to March 2nd, 2021, at the Hilton Hotel in Buenos Aires (Argentina) (due to the coronavirus pandemic). That is why at solaci.org we talked to Dr. Anibal Damonte, President<a href="https://solaci.org/en/2019/09/11/to-the-beat-of-solaci-caci-2020-an-interview-with-dr-anibal-damonte/" title="Read more" >...</a>